# Vaccine Therapy in Treating Patients With Stage IV Melanoma

> **NCT00023647** · PHASE1 · COMPLETED · sponsor: **Mannkind Corporation** · enrollment: 26 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** Synchrotope TA2M
- **BIOLOGICAL:** Synchrotope TA2M
- **BIOLOGICAL:** Synchrotope TA2M

## Key facts

- **NCT ID:** NCT00023647
- **Lead sponsor:** Mannkind Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-07
- **Primary completion:** 2002-04
- **Final completion:** 2002-11
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2012-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00023647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00023647, "Vaccine Therapy in Treating Patients With Stage IV Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00023647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*